食管原发性小细胞神经内分泌癌78例临床特点及预后分析

Clinical features and prognosis analysis of 78 patients with esophageal primary small cell neuroendocrine carcinoma

目的探讨食管原发性小细胞神经内分泌癌(esophageal primary small cell neuroendocrine carcinoma,ESCNC)的临床特征、治疗方法及预后情况。方法回顾性分析2011年10月至2017年6月郑州大学第一附属医院经病理证实的ESCNC患者78例的临床及随访资料。结果本组患者1、3、5年生存率分别为55.70%、23.87%和13.82%。局限期与广泛期患者的中位生存时间分别为14个月、7个月(P<0.05)。局限期患者行单一治疗的中位生存时间为9个月,综合治疗为17个月(P<0.05)。结论 ESCNC是一种罕见且具高度侵袭性的恶性肿瘤,组织病理学及免疫组织化学检查是其确诊的主要手段。目前综合性治疗是局限期患者最好的选择。

Objective To investigate the clinical features,treatment methods and prognosis in patients with esophageal primary small cell neuroendocrine carcinoma（ESCNC）. Methods The clinical data and follow-up data of 78 patients with ESCNC were collected and analyzed retrospectively from Oct. 2011 to Jun. 2017 in the First Affiliated Hospital of Zhengzhou University. Results The 1-year,3-year and 5-year survival rates were 55. 70%,23. 87% and13. 82%,respectively. The median survivals of locally stage patients and advanced stage patients were 14 months and 7 months（P〈0. 05）. The median survivals of locally stage patients with single treatment and with comprehensive treatment were 9 months and 17 months,respectively（P〈0. 05）. Conclusion ESCNC is rare with high degree of malignancy. Diagnosis depends on histopathology and immunohistochemistry. At present,comprehensive treatment is the best choice for the patients in the locally stage.